The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global cell-based assay market reached a value of US$ 18.9 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 31.4 Billion by 2027, exhibiting at a CAGR of 8.78% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The market is currently being catalysed by a number of factors, this includes rising investments in research and development, adoption of high throughput screening methods, increasing prevalence of various chronic diseases, growth in drug discovery activities, and the various advantages that cell-based assays offer over alternative technologies.
Cell-based assays refer to any experiment that use live cells. The basic techniques include a variety of assays that can be used for the purpose of measuring cell toxicity, proliferation, motility as well as production of a particular cellular product and cellular morphology. Cell-based assays provide a closer representation of the real life model since it employs live cells during experimentation. Cell-based assays have grown to become a versatile tool in healthcare research and development, particularly in the experiments which are designed to understand functionalities of specific cells like antibodies or drug efficacy on a group of cells.
There has been a significant increase in R&D funding by various public and private organisations so as to develop better and safer drugs. Moreover, technological advancements in cell-based assays have enabled researchers to start using this technology for drug discovery and toxicology studies. Another major factor catalysing the growth of the market is the rising prevalence of lifestyle diseases such as arthritis, diabetes, epilepsy, cancer, cardiovascular diseases, etc. which still have large unmet needs and have led to continuous investments in R&D. In addition, an increase in the adoption of the cell-based assay techniques for high throughput screening methods like toxicity studies, drug screening, in vitro testing, etc. are further driving this market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global cell-based assay market, along with forecasts at the global and regional level from 2022-2027. Our report has categorized the market based on product and services, technology, application and end-user.
Breakup by Product and Services:
Based on the product and services, the market has been segmented as consumables, instruments, services and software. Currently, the consumables segment dominates the market, holding the largest share.
Breakup by Technology:
Based on the technology, the market has been segmented as automated handling, flow cytometry, label-free-detection, high-throughput screening, and others.
Breakup by Application:
Based on the application, the market has been segmented as drug discovery, basic research, ADME studies, predictive toxicology and others. Currently, the drug discovery segment dominates the market, holding the largest share.
Breakup by End-User:
On the basis of end-user, the market has been segmented as pharmaceutical and biotechnology companies; academic and government institutions; contract research organizations; and others.
Breakup by Region:
Region-wise, the market has been segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. Amongst these, North America is the leading market, accounting for the majority of the market share.
The competitive landscape of the market has also been examined with some of the key players being Becton Dickinson and Company, GE Healthcare Biopharma (Danaher Corporation), Thermo Fisher Scientific Inc., Merck Group, Perkinelmer Inc., Charles River Laboratories Inc., Lonza Group Ltd., Cell Signaling Technology Inc., Promega Corporation, Cell Biolabs Inc., Eurofins DiscoverX Corporation, Bio-Rad Laboratories Inc., Corning Inc. and F. Hoffmann-La Roche AG (Roche Holding AG).
This report provides a deep insight into the global cell-based assay market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the cell-based assay industry in any manner.
|Base Year of the Analysis||2021|
|Segment Coverage||Product and Services, Technology, Application, End-User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Companies Covered||Becton Dickinson and Company, GE Healthcare Biopharma (Danaher Corporation), Thermo Fisher Scientific Inc., Merck Group, Perkinelmer Inc., Charles River Laboratories Inc., Lonza Group Ltd., Cell Signaling Technology Inc., Promega Corporation, Cell Biolabs Inc., Eurofins DiscoverX Corporation, Bio-Rad Laboratories Inc., Corning Inc. and F. Hoffmann-La Roche AG (Roche Holding AG).|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at